VEA
ENTA icon

Virtus ETF Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Virtus ETF Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,784
Closed -$143K – 439
2023
Q3 		$143K Sell
12,784
-1,654
-11% -$26.6K 0.09% 315
2023
Q2 		$309K Buy
14,438
+7,514
+109% +$222K 0.18% 200
2023
Q1 		$280K Buy
6,924
+124
+2% +$5.92K 0.15% 253
2022
Q4 		$316K Buy
6,800
+917
+16% +$41.8K 0.17% 243
2022
Q3 		$305K Buy
5,883
+85
+1% +$4.97K 0.12% 274
2022
Q2 		$274K Buy
5,798
+445
+8% +$24.2K 0.1% 275
2022
Q1 		$381K Hold
5,353
– – 0.17% 155
2021
Q4 		$400K Sell
5,353
-4,246
-44% -$333K 0.15% 148
2021
Q3 		$545K Sell
9,599
-884
-8% -$43.7K 0.24% 126
2021
Q2 		$461K Sell
10,483
-4,238
-29% -$208K 0.19% 177
2021
Q1 		$726K Buy
14,721
+400
+3% +$20K 0.31% 103
2020
Q4 		$603K Buy
14,321
+2,275
+19% +$100K 0.25% 113
2020
Q3 		$551K Buy
12,046
+1,015
+9% +$49.2K 0.29% 123
2020
Q2 		$554K Buy
11,031
+2,200
+25% +$114K 0.26% 133
2020
Q1 		$454K Sell
8,831
-745
-8% -$39.7K 0.19% 180
2019
Q4 		$592K Buy
9,576
+1,497
+19% +$92.8K 0.1% 190
2019
Q3 		$485K Sell
8,079
-1,354
-14% -$101K 0.1% 182
2019
Q2 		$796K Sell
9,433
-1,201
-11% -$108K 0.17% 185
2019
Q1 		$1.02M Buy
10,634
+2,494
+31% +$224K 2.16% 5
2018
Q4 		$577K Buy
8,140
+1,088
+15% +$83.4K 0.1% 54
2018
Q3 		$603K Buy
7,052
+475
+7% +$47.6K 0.06% 101
2018
Q2 		$762K Sell
6,577
-9,036
-58% -$902K 0.67% 61
2018
Q1 		$1.26M Sell
15,613
-1,918
-11% -$148K 1.1% 15
2017
Q4 		$1.03M Sell
17,531
-14,704
-46% -$736K 1.29% 13
2017
Q3 		$1.51M Hold
32,235
– – 0.2% 34
2017
Q2 		$1.16M Sell
32,235
-286
-0.9% -$9.15K 0.17% 39
2017
Q1 		$1M Buy
32,521
+3,127
+11% +$97.4K 0.18% 68
2016
Q4 		$985K Buy
29,394
+2,745
+10% +$78.7K 0.29% 51
2016
Q3 		$709K Buy
26,649
+3,357
+14% +$78K 0.34% 51
2016
Q2 		$514K Buy
23,292
+4,603
+25% +$120K 0.38% 54
2016
Q1 		$549K Buy
+18,689
New +$520K 0.76% 30

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtus ETF Advisers's ENTA Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 12,784 shares — an estimated $143K sold.

Virtus ETF Advisers first reported a position in ENTA in Q1 2016 and held it in 31 quarters. The position peaked at $1.51M in Q3 2017. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 12,784 Enanta Pharmaceuticals shares in Q4 2023, an estimated $143K.
  • Virtus ETF Advisers first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 31 quarters.
  • Virtus ETF Advisers's Enanta Pharmaceuticals position peaked at $1.51M in Q3 2017.
  • 105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.